枳实薤白桂枝汤对不稳定型心绞痛患者MMP-9/TIMP-1的影响被引量：13

Effect of Zhishi Xiebai Guizhi Decoction on MMP-9,TIMP-1 Levels and Gene Expression in Patients with Unstable Angina

导出

摘要目的:探讨枳实薤白桂枝汤对血瘀、痰浊、气滞、寒凝为主的不稳定型心绞痛(UA)患者基质金属蛋白酶9(MMP-9)、基质金属蛋白酶抑制剂1(TIMP-1)水平及其基因表达的影响及其作用机制。方法:UA患者60例,按随机原则,将患者划分为对照组和治疗组,每组各30例。酶联免疫标记(ELISA)测定血清MMP-9,TIMP-1水平,实时荧光定量PCR技术进行相对定量检测MMP-9,TIMP-1基因表达,比较两组MMP-9,TIMP-1水平及其基因表达的变化。结果:两组患者症候积分较治疗前均有改善(P<0.05),且治疗组优于对照组(P<0.05)。两组患者MMP-9,TIMP-1水平较治疗前均有改善(P<0.05),且治疗组优于对照组(P<0.05)。两组患者MMP-9,TIMP-1 mRAN较治疗前均有改善(P<0.05),MMP-9/TIMP-1 mRAN比较,治疗组优于对照组(P<0.05)。结论:在规范化治疗的基础上加用枳实薤白桂枝汤可进一步改善UA患者MMP-9,TIMP-1水平及其基因表达,促进粥样斑块的稳定性。 Objective： To explore the effect and mechanism of Zhishi Xiebai Guizhi decoction on matris metalloproteinases-9（MMP-9）,tissue inhibitor of metalloproteinase（TIMP-1） levels and gene expression in patients with blood stasis,sputum,qi stagnation,cold obstruction unstable angina（UA）.Method： Sixty UA patients were divided into control group（30） and treatment group（30） randomly.ELISA was used to determine the serum MMP-9,TIMP-1 levels.Real time fluorescent quantitative PCR was used to determine MMP-9,TIMP-1 gene expression.Compared the serum MMP-9,TIMP-1 levels and gene expression from the two group.Result： The two groups had significant improvements in Symptom integra after treatment（P 0.05）,and the treatment group were superior to the control group（P 0.05）.The two groups had significant improvements in Serum levels of MMP-9,TIMP-1 after treatment（P 0.05）.and the treatment group were superior to the control group（P 0.05）.The two groups had significant improvements in MMP-9,TIMP-1 mRAN after treatment（P 0.05）.The treatment group were superior to the control group in MMP-9 / TIMP-1mRAN（P 0.05）.Conclusion： Based on the standardization of treatment,Zhishi Xiebai Guizhi decoction can improve the serum MMP-9,TIMP-1 levels and gene expression in patients with blood stasis,sputum,qi stagnation,cold obstruction UA,and advance the stability of atherosclerosis plaque.

作者戴飞陆曙苏伟龚少愚

机构地区南京中医药大学南京中医药大学附属无锡市中医医院

出处《中国实验方剂学杂志》 CAS 北大核心 2013年第14期307-310,共4页 Chinese Journal of Experimental Traditional Medical Formulae

关键词枳实薤白桂枝汤不稳定型心绞痛基质金属蛋白酶-9 基质金属蛋白酶抑制剂-1 Zhishi Xiebai Guizhi decoction unstable angina MMP-9 TIMP-1

分类号 R287 [医药卫生—中药学]

引文网络
相关文献

参考文献10

1姬媛媛,刘俊田,王志东.中药防治动脉粥样硬化研究现状述评[J].中国实验方剂学杂志,2006,12(4):58-60. 被引量：7
2红梅.丹蒌片对大鼠心肌梗死面积和心室重构的影响[J].中国实验方剂学杂志,2011,17(10):208-211. 被引量：25
3Newby A C. Dual role of matrix metallop roteinases (matrixins) in intimal thickening and atherosclerotic p laque rupture[ J]. Physiol Rev, 2005,85 ( 1 ) : 1.
4Chow A K, Cena J, Schulz R. Acute actions and novel targets of matrix metallop roteinases in the heart and vasculature[J]. Br J Pharmacol,2007,152 (2) :189.
5Kuge Y, Takai N, Ishino S, et al. Distribution profiles of membrane type-1 matrixmetallop roteinase (MT1- MMP ) , matrix metallop roteinase2 ( MMP-2 ) and cyclooxygenase-2 ( COX-2 ) in rabbit atherosclerosis: comparison with plaque instability analysis [ J ]. Biol Pharm Bull, 2007, 30 (9) :1634.
6Feldman L J, Mazighi M, Scheuble A, et al. Differential expression of matrix metalloproteinases after stent implantation and balloon angioplasty in the hypercholesterolemic rabbit [ J ]. Circulation, 2001,103 (25) :3117.
7Creemers E E, Cleutjens J P, Smits J F, et al. Matrix metalloproteinase inhibition after myocardial infarction:a new approach to prevent heart failure [ J]. Circ Res, 2001, 89 (2) :201.
8Konstantino Y, Nguyen T T, Wolk R, et al. Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease [ J ]. Biomarkrs, 2009,14 ( 2 ) : 118.
9Visse R, Hideaki N. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochrmistry [ J ]. Circ Res, 2003,92 (3) :827.
10李如意,李秀芳,刘永欣,齐晓勇.联合检测血清炎症因子对急性冠脉综合征的预测价值[J].江苏医药,2011,37(2):190-192. 被引量：10

二级参考文献31

1杨俊卿,周岐新,李远宗.姜黄提取物对实验性动物高脂血症的防治作用研究[J].中国药房,2004,15(10):600-602. 被引量：19
2王绿娅,王大全,秦彦文,荆涛,潘晓冬,杜兰平,石风茹,张兰珍.余甘子对动脉粥样硬化家兔血浆总抗氧化能力及丙二醛和内皮素1水平的影响(英文)[J].中国临床康复,2005,9(7):253-256. 被引量：11
3ZHANG Xing-wei,GE Jun-bo,YANG Jian-min,GE Lei,WANG Ning-fu,GAO Yan,LI Pei-zhang,PAN Hao,TONG Guo-xin,ZHOU Liang,YE Xian-hua,XU Jian.Relationship between hs-CRP, proMMP-1, TIMP-1 and coronary plaque morphology: intravascular ultrasound study[J].Chinese Medical Journal,2006(20):1689-1694. 被引量：23
4李才王丽娟赵志涛.灶状心肌坏死的定量组织学测量——逐区点测量法[J].白求恩医科大学学报,1988,14:314-316.
5Moreno PR. Pathophysiology of plaque disruption and thrombosis in acute isehemie syndromes[J].J Stroke Cerebrovase Dis,2001,10(2 Pt 2) :2-9.
6Mauriello A, Sangiorgi G, Fratoni S, et al. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree[J]. J Am Coll Cardiol,2005,45(10): 1585-1593.
7Espliguero RA, Avanzas P, Sales JC, et al. C-reactive protein elevation and disease activity in patients with coronary artery disease[J]. European Heart Joumal,2004,25(5):401-408.
8Konstantino Y, Nguyen TT,Wolk R, et al. Potential implications of matrix metalloproteinase-9 in assessment and treatment of coronary artery disease[J]. Biomarkrs, 2009,14(2) : 118-129.
9Cheng M,Hashrnl S, Mao X,et al. Relationships of adiponeetin and matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 ratio with coronary plaque morphology in patients with acute coronary syndrome[J]. Can J Cardiol,2008,24(5) : 385-390.
10Korkmaz S,Radovits T,Barnucz E,et al.Pharmacological activation of soluble guanylate cyclase protects the heart against ischemic injury[J].Circulation,2009,120:677.